GYRE has been in the news 321% more than usual
Dec 10, 2025, 5:32 AM
-12.48%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Gyre Therapeutics has not been explicitly mentioned in the provided information, but related entities like Andelyn Biosciences and Jaguar Gene Therapy are collaborating on a gene therapy for Phelan-McDermid syndrome affecting autism. Additionally, Astrin Biosciences is enhancing early cancer detection and treatment through a newly formed Scientific Advisory Board, while Pillar Biosciences and AstraZeneca are expanding their liquid biopsy program to improve diagnostics for cancer.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.